06 May NICE has moved MTG19 to become HTG344 – with no change to the guidance itself
The update reflects the streamlined NICE HealthTech programme, which brings together diagnostics, interventional procedures and medical technologies to improve access to relevant guidance.
Originally published in June 2014, the guidance supports use of the geko® device for reducing thromboembolism risk in patients where other prophylaxis methods are impractical or contraindicated.
A NICE costing statement initially estimated a cost saving of £197 per patient. Updated independent analysis now puts the figure at £384 per patient when the geko device is used for six days versus no VTE prophylaxis, and would be cost saving for up to 19 days of use. These savings are driven by reduced DVT and PE risk and fewer VTE-related complications such as post-thrombotic syndrome, and shorter hospital stays.
Reducing VTE risk in acute stroke patients
Firstkind partnered with a major NHS Trust to audit use of the geko device in acute stroke care. Current practice, based on the CLOT-3 study, indicates 31% of patients cannot tolerate or are contraindicated for IPC, with a symptomatic VTE risk of 8.7%—highlighting a clear unmet need.
The audit found 36% of patients were unable to use IPC. Within this group, the geko device was evaluated and shown to be as effective as IPC in reducing VTE, whilst reducing the unmet need VTE risk to 1.5%. It was well tolerated and provided a viable alternative, enabling VTE prophylaxis for patients who would otherwise receive none.
Logo copyright: National Institute for Health and Care Excellence
No Comments